Biomerica (BMRA) Cost of Revenue (2010 - 2026)

Biomerica (BMRA) has 17 years of Cost of Revenue data on file, last reported at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 6.27% year-over-year to $1.0 million; the trailing twelve-month figure through Feb 2026 stood at $4.1 million (down 15.75% YoY), and the FY2025 full-year result was $4.8 million, changed 0.19% from the prior year.
• Cost of Revenue retreated to $1.0 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $6.0 million in Q1 2022 to a low of $956000.0 in Q3 2025.
• A 5-year average of $1.7 million and a median of $1.2 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 349.58% in 2022 and sank 83.45% in 2023, its largest moves.
• Tracing BMRA's Cost of Revenue over 5 years: stood at $1.1 million in 2022, then advanced by 9.91% to $1.2 million in 2023, then declined by 3.46% to $1.2 million in 2024, then retreated by 3.34% to $1.2 million in 2025, then declined by 11.04% to $1.0 million in 2026.
• Business Quant data shows BMRA's Cost of Revenue at $1.0 million in Q1 2026, $1.2 million in Q4 2025, and $956000.0 in Q3 2025.